HomeBIOTECHNOLOGY
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
Aegea Biotechnologies Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition
Aegea Biotechnologies notes XPRIZE is renowned for its worldwide competitions to solve humanity's most important challenges. The $5 million, XPRIZE Rapid COVID Testing competition was launched this summer to accelerate the development of high-quality COVID-19 testing that is affordable, easy to use, and that has a fast turnaround time.
ARUP Laboratories Now Offers COVID-19 Saliva Testing – Available with Preapproval to ARUP Clients Nationwide
ARUP Laboratories will perform the test only on saliva specimens collected using an ARUP collection kit with a healthcare provider present. ARUP validated the test using its kit on high-throughput instruments, and cannot perform it on other saliva specimens without jeopardizing quick turnaround times, said Adam Barker, Ph.D., director of ARUP's new COVID-19 Rapid Response Lab.
SafeSite Takes On COVID-19 with Protocol-Oriented Testing
SafeSite was formed by an assembly of medical professionals, all frustrated with the lack of cohesive and reliable COVID-19 testing procedures.
Vivera Pharmaceuticals Announces a New Diagnostic Test Solution For COVID-19
Access to reliable testing allows for better patient management and more informed public health decisions. By utilizing OmeCare's dedicated CLIA-certified and CAP-accredited facility, Vivera and OmeCare are helping to eliminate excessive wait times.
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
The study, containing 15 patients, is scheduled to continue for an additional 6 months.
SQI Diagnostics Expanding Its Proprietary Rapid Diagnostic Testing Portfolio Targeting Organ Transplant, Autoimmune Disease and Serological Testing
SQI Diagnostics, Inc. CEO Mr. Robert L. Chioini stated, “Within our organ transplant, autoimmune disease, and serological testing business units we have multiple products in clinical development, and we believe these advanced tests have the potential to offer patients and consumers significant benefit once they receive regulatory approval.
Enesi Pharma to Develop Thermostable, Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide
Enesi Pharma to Develop Thermostable, Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide
Oncimmune Holdings Reports Autoantibody Profiling Program Agreement Signed with ImmunoINSIGHTS, World-Leading BioPharm Company
Oncimmune CEO dam M Hill said: "We are pleased to announce this partnership between our ImmunoINSIGHTS business and another world-leading biopharmaceutical company."
Micron Biomedical Progresses with Clinical Evaluation of Its Technology for Measles-Rubella Vaccination
Micron Biomedical reports their applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income countries.
